NICE approves immunotherapy combination for advanced melanomaBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i3421 (Published 17 June 2016) Cite this as: BMJ 2016;353:i3421
- Jacqui Wise
A combination of two immunotherapy drugs for treating advanced melanoma has been recommended by the National Institute for Health and Care Excellence for use by the NHS in England.
The combination of nivolumab and ipilimumab was fast tracked for appraisal by NICE only a few months after it was licensed. Both drugs boost the activity of the immune system against cancer cells. Trials have shown that the combination can delay progression of advanced (unresectable or metastatic) melanoma by an average of eight months compared with standard treatment.
NICE published …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial